A prospective multicenter single-arm trial including 635 prostate cancer patients demonstrated the accuracy of PSMA-PET in detecting prostate cancer lesions after recurrence after previous radical surgery or radiotherapy [87]. The gene discussed is FOLH1; the disease is prostate carcinoma.